local_hospital

Sint Maartenskliniek Stichting

Address
lock Available on a paid plan

Musculoskeletal Diseases

At Sint Maartenskliniek Stichting in Ubbergen, much of the clinical research focuses on musculoskeletal diseases, especially osteoarthritis, hand osteoarthritis, and related joint conditions. These studies are designed to evaluate treatments that may reduce pain, improve function, and delay the need for joint replacement.

  • Research on osteoarthritis and hand osteoarthritis to test symptom relief and longer-term joint outcomes
  • Studies assessing whether existing therapies can improve pain control and preserve mobility
  • Clinical work aimed at better understanding treatment effectiveness in everyday rheumatology care

This area reflects a strong interest in practical treatment strategies for common joint disorders, with a clear focus on improving daily life for people living with chronic musculoskeletal disease.

Immune System Diseases

The site also conducts research in immune system diseases, particularly rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and polymyalgia rheumatica. These trials are centered on finding better ways to control inflammation, reduce steroid use, and optimize long-term treatment.

  • Studies in rheumatoid arthritis exploring treatment adjustment and disease control
  • Research in psoriatic arthritis and axial spondyloarthritis focused on treatment reduction strategies
  • Trials in polymyalgia rheumatica evaluating therapies that may improve remission and reduce dependence on corticosteroids

These investigations support more personalized care for inflammatory conditions, with the aim of maintaining disease control while limiting unnecessary medication exposure.

Bacterial Infections and Mycoses

Another important research area at the hospital/clinic is bacterial infection research, especially prosthetic joint infection. The trials in this field are examining whether newer antibiotic approaches can be as effective as traditional combination treatments after joint replacement infection.

  • Clinical research on prosthetic joint infection to compare treatment approaches for infected implants
  • Studies focused on improving antibiotic selection for better recovery and fewer complications
  • Work aimed at strengthening infection management after orthopedic procedures

This line of research is important for helping patients recover safely after joint surgery and for improving the treatment of difficult-to-manage bacterial infections.

Analytical, Diagnostic and Therapeutic Techniques and Equipment

The clinical trial portfolio also includes research into therapeutic techniques and treatment optimization, with studies assessing how dosing strategies and targeted therapies can improve outcomes in rheumatologic diseases. These projects look at better ways to use established medicines more effectively.

  • Trials evaluating treatment optimization in rheumatoid arthritis through dose adjustment strategies
  • Research on targeted therapy use in polymyalgia rheumatica to improve disease control
  • Studies testing whether treatment reduction can remain effective in stable inflammatory disease

This area highlights a practical approach to improving care by refining how therapies are used in real-world rheumatology practice.

Site Overview

assignment
9
connected trials
corporate_fare
3
sponsors
science
28
IMPs

Activity Indicator

Last 6 months

1
Trials started
0% vs previous period.
1
Trials started 6–12 months ago
9
Total trials linked
Active
trending_flatStable0%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 therapeutic areas and 15 of 28 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
6
Sponsors (total)
3
Active sponsors
3

Sponsor Network

Top 3 by active trials.

lock +2 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 271 other sites in The Netherlands

description
Trial volume
9
Outperforms 68% of sites
public
Therapeutic diversity
4areas
Outperforms 62% of sites
groups
Sponsor diversity
3sponsors
Outperforms 54% of sites

Therapeutic Area Benchmark — The Netherlands

Select a therapeutic area to compare against other sites in The Netherlands.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: The Netherlands

Market Share

Country: The Netherlands

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Sint Maartenskliniek Stichting

lock Showing 1 of 9 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Concentration-Guided Tocilizumab Dose Reduction Versus Standard Dosing in Rheumatoid Arthritis: A Randomized, International, Multicenter, Non-Inferiority TrialReade revalidatie & reumatologie centrum te AmsterdamPhase IIINot Yet Recruiting

IMP list

lock Showing 1 of 28 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Rituximab2Unknown2023-02-012023-02-09

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.